Active	Status	Sponsor type	Region	Phase	Filter
3 Active 14 Inactive 17 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
niclosamide (ANA001) / Dong-A
NCT04603924: Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients	Completed	2/3	49	US	Niclosamide, ANA001, Placebo, Matching Placebo to ANA001	NeuroBo Pharmaceuticals Inc.	COVID-19	02/22	02/22
NCT04705415: A Single and Multiple Ascending Dose Study of Niclosamide in Healthy Volunteers	Completed	1	54	US	Niclosamide, ANA001, Placebo, Matching Placebo to ANA001	NeuroBo Pharmaceuticals Inc.	Healthy	10/21	10/22
NCT05188170: Niclosamide in Pediatric Patients With Relapsed and Refractory AML	Recruiting	1	16	US	Niclosamide	Stanford University	Acute Myeloid Leukemia (AML)	07/25	12/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
niclosamide (ANA001) / Dong-A
NCT04603924: Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients	Completed	2/3	49	US	Niclosamide, ANA001, Placebo, Matching Placebo to ANA001	NeuroBo Pharmaceuticals Inc.	COVID-19	02/22	02/22
NCT04705415: A Single and Multiple Ascending Dose Study of Niclosamide in Healthy Volunteers	Completed	1	54	US	Niclosamide, ANA001, Placebo, Matching Placebo to ANA001	NeuroBo Pharmaceuticals Inc.	Healthy	10/21	10/22
NCT05188170: Niclosamide in Pediatric Patients With Relapsed and Refractory AML	Recruiting	1	16	US	Niclosamide	Stanford University	Acute Myeloid Leukemia (AML)	07/25	12/26